Beta-lactam-induced severe neutropaenia: a descriptive study.
Adolescent
Adult
Adverse Drug Reaction Reporting Systems
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ adverse effects
Child
Child, Preschool
Databases, Factual
Drug Substitution
Female
France
/ epidemiology
Humans
Male
Middle Aged
Neutropenia
/ chemically induced
Pharmacovigilance
Prognosis
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Time Factors
Young Adult
beta-Lactams
/ adverse effects
adverse drug reaction
beta-lactam
neutropaenia
severity
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
12
07
2018
revised:
19
09
2018
accepted:
01
10
2018
pubmed:
6
10
2018
medline:
27
6
2019
entrez:
6
10
2018
Statut:
ppublish
Résumé
The objectives of this study were to describe the characteristics and natural history of beta-lactam-induced severe neutropaenia and to evaluate the risk of recurrences after another beta-lactam readministration. Reports of pure agranulocytosis associated with a beta-lactam exposure within the 10 days preceding the neutropaenia were extracted from the French Pharmacovigilance Database over the year 2010. Cases with another evident cause or more likely attributable to another drug were excluded. Data were analyzed for demographics, clinical and biological features, prognosis factors, granulocyte colony stimulating factors administration and outcome. Sixty-two cases were included (median age: 65 years). The median duration of treatment before neutropaenia was 16 days. In 47% of cases, the diagnosis was made on a systematic blood cell count. The median neutrophil count at nadir was 0.125 × 10
Substances chimiques
Anti-Bacterial Agents
0
beta-Lactams
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-231Informations de copyright
© 2018 Société Française de Pharmacologie et de Thérapeutique.